Can ketamine treat chronic fatigue syndrome (ME/CFS)?

Ketamine is not FDA-approved for ME/CFS, and no large randomized controlled trials have tested it specifically for this condition. However, emerging research from 2026 suggests that ketamine's ability to block NMDA receptors, reduce neuroinflammation, and modulate glutamate signaling may address several mechanisms believed to drive ME/CFS symptoms including fatigue, brain fog, and pain. At Music City Ketamine, we discuss this research honestly with patients and help them weigh the potential benefits against the current limitations of the evidence.

How might ketamine help with ME/CFS brain fog?

ME/CFS patients often show reduced glutamate activity in the prefrontal cortex, the brain region responsible for executive function, working memory, and attention. Ketamine has been shown to increase glutamate release in the prefrontal cortex through a rebound effect after NMDA receptor blockade, which may help restore cognitive function. Ketamine also reduces pro-inflammatory cytokines that contribute to neuroinflammation, another suspected driver of the cognitive difficulties ME/CFS patients describe.

How many ketamine infusions would someone with ME/CFS need?

There is no established protocol specifically for ME/CFS. A common approach for related conditions involves a series of six infusions over two to three weeks, with each session lasting approximately 40 minutes at a subanesthetic dose of 0.5 mg/kg. Response is assessed after the initial series, and maintenance infusions are individualized. Some patients notice improvement within the first few sessions, while others require the full series before experiencing meaningful change.

Does insurance cover ketamine for chronic fatigue syndrome?

Insurance typically does not cover IV ketamine infusions for ME/CFS. Ketamine is FDA-approved only as an anesthetic, and its use for fatigue, pain, and mood conditions is considered off-label. At Music City Ketamine, we provide documentation that patients can submit to their insurance or use with HSA/FSA accounts. We also offer transparent pricing so there are no surprises.

Is ketamine safe for someone with ME/CFS who is sensitive to medications?

Many ME/CFS patients are more sensitive to medications than the general population, and we take that seriously. IV ketamine allows precise dose control, meaning we can start at a lower dose and titrate carefully based on how you respond. A Cleveland Clinic study of over 1,000 patients receiving subanesthetic ketamine found 86.1% adherence with no serious adverse effects. Our clinic is staffed by a CRNA who oversees the infusion, with your vitals monitored throughout and dosing adjusted in real time.

Ketamine for Chronic Fatigue Syndrome (ME/CFS)

What ME/CFS Actually Is

Myalgic encephalomyelitis/chronic fatigue syndrome is one of the most misunderstood conditions in medicine. For years, patients were told their fatigue was psychological, that they needed to exercise more, or that nothing was wrong. That era is ending, though not fast enough.

ME/CFS is a complex, multi-system disease. The hallmark symptom is post-exertional malaise: physical or cognitive activity that a healthy person would handle without difficulty triggers a disproportionate crash that can last days or weeks. Beyond that, patients deal with profound fatigue that does not improve with rest, cognitive impairment often called brain fog, unrefreshing sleep, orthostatic intolerance, muscle and joint pain, and heightened sensitivity to light, sound, and temperature.

The Centers for Disease Control estimates that 836,000 to 2.5 million Americans have ME/CFS, and the majority remain undiagnosed. Treatments are limited. There is no FDA-approved medication for the condition. Most patients piece together symptom management strategies and try to stay within their energy limits. Many are housebound. Some are bedbound.

This is the context in which we want to discuss ketamine. Not as a cure, but as a treatment that may address several of the biological mechanisms now believed to drive ME/CFS symptoms.

The Neuroinflammatory Machinery Behind the Fatigue

Over the past decade, research has converged on a picture of ME/CFS as a condition involving chronic neuroinflammation, immune dysregulation, and central nervous system hyperactivation. The details matter because they explain why ketamine is even being considered for this condition.

A 2026 article from Rutgers University pulled together several lines of evidence suggesting that NMDA receptor overactivation is a key contributor to ME/CFS symptoms. Here is the logic:

NMDA receptors are glutamate receptors found throughout the brain and spinal cord. When they are activated appropriately, they support learning, memory, and normal neural function. When they are chronically overactivated, they allow excessive calcium ion influx into neurons, leading to excitotoxicity, oxidative stress, and cell damage.
In ME/CFS, evidence suggests this overactivation contributes to central nervous system hyperactivity that manifests as chronic pain, cognitive dysfunction, fatigue, and sensory sensitivity.
Pro-inflammatory cytokines, which are consistently elevated in ME/CFS patients, further sensitize NMDA receptors, creating a feedback loop: inflammation increases receptor activity, which produces more neural damage, which triggers more inflammation.

This is not a single broken wire. It is a system that has gotten stuck in a self-reinforcing state. The fatigue, the brain fog, the pain, and the sensory overload are all downstream consequences of the same underlying process.

If you have read our article on central sensitization, this pattern will look familiar. An April 2026 systematic review of randomized controlled trials published between 2005 and 2025 confirmed that subanesthetic ketamine modulates central sensitization through NMDA receptor antagonism. The overlapping neuro-inflammatory pathways between chronic pain and chronic fatigue are increasingly difficult to ignore.

How Ketamine Intervenes

Ketamine is a noncompetitive NMDA receptor antagonist. That means it physically blocks the NMDA receptor channel, reducing the calcium ion influx that drives excitotoxicity and neural hyperactivation. This is the most direct mechanism by which ketamine could help ME/CFS, and it has been well characterized in pain and mood disorder research for over two decades.

But ketamine does more than block a single receptor. Several of its properties are relevant to ME/CFS pathology:

Anti-inflammatory effects. Ketamine reduces pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1 beta. These are the same cytokines consistently found to be elevated in ME/CFS patients, and they contribute directly to fatigue, brain fog, and muscle pain. By dampening this inflammatory signaling, ketamine may help interrupt the feedback loop that keeps the immune system in a state of chronic activation.

Glutamate modulation in the prefrontal cortex. This is a more nuanced point. While ketamine blocks NMDA receptors, the downstream effect is a rebound increase in glutamate release, particularly in the prefrontal cortex. ME/CFS patients often show reduced prefrontal cortex activity, which correlates with the executive dysfunction, poor concentration, and difficulty with word retrieval that patients describe as brain fog. The increase in prefrontal glutamate signaling may help restore some of that lost cognitive function.

Fatigue reduction independent of mood effects. A study of patients with bipolar disorder found that ketamine had a strong, prolonged fatigue-reducing effect that was independent of its antidepressant properties. This is an important distinction. Many ME/CFS patients are told their fatigue is really depression, which it is not. The fact that ketamine can reduce fatigue through a separate mechanism from its mood effects suggests it may be addressing the fatigue itself, not just improving how patients feel about being tired.

For a deeper look at the receptor-level mechanisms, our article on how ketamine works covers the pharmacology in more detail.

What the Clinical Evidence Shows So Far

We want to be straightforward about where the evidence stands. There are no completed large-scale randomized controlled trials of ketamine specifically for ME/CFS. The research that exists comes from adjacent conditions, mechanistic studies, and clinical observations.

The strongest clinical data comes from pain and mood research. A Cleveland Clinic study involving 1,034 patients receiving subanesthetic ketamine at 0.5 mg/kg over 40 minutes for 5 consecutive days found 86.1% adherence and no serious adverse effects. While this study focused on pain and depression rather than ME/CFS specifically, the safety profile at this dose and duration is well established.

The April 2026 systematic review of randomized controlled trials spanning 2005 to 2025 confirmed ketamine's ability to modulate central sensitization via NMDA receptor antagonism. Given that central sensitization is increasingly recognized as a feature of ME/CFS and not just chronic pain, this evidence has implications beyond the conditions studied.

The Rutgers University article from 2026 explicitly proposed ketamine as a candidate treatment for ME/CFS based on the overlap between ketamine's mechanisms and ME/CFS pathology. This is a hypothesis paper rather than a clinical trial, but it represents a serious academic institution making a mechanistic case for investigation.

A rapid reduction in fatigue could serve as a therapeutic bridge, allowing patients to engage in rehabilitative therapies and functional activities that their baseline exhaustion currently prevents. Rutgers University, 2026

This idea of a therapeutic bridge is worth sitting with. Many ME/CFS patients know what they should be doing to improve their condition, whether that is graded exercise therapy, cognitive behavioral approaches, or simply maintaining basic daily activities. But the fatigue itself prevents them from doing any of it. If ketamine could reduce that fatigue enough to make other treatments possible, it would not need to be a standalone solution to be genuinely useful.

What Treatment Looks Like in Practice

At Music City Ketamine in Franklin, Tennessee, we administer IV ketamine in a clinical setting with continuous monitoring by our CRNA. For conditions adjacent to ME/CFS, a typical protocol involves:

An initial series of six infusions over two to three weeks
Each infusion lasts approximately 40 minutes at a subanesthetic dose (0.5 mg/kg, adjusted for individual response)
Assessment after the series to determine whether and how much benefit occurred
Maintenance infusions individualized based on how long relief lasts

We recognize that ME/CFS patients often have heightened sensitivity to medications. IV administration gives us precise control over dosing. We can start lower than the standard dose and titrate carefully, watching for both benefit and side effects in real time. You are never left alone during an infusion.

Common side effects during the infusion include mild dissociation, nausea (which we can treat), and temporary increases in blood pressure and heart rate. These resolve within an hour or two of the infusion ending. The Cleveland Clinic study's 86.1% adherence rate and absence of serious adverse events provide reasonable reassurance about safety at subanesthetic doses.

Honest Limitations

We believe in giving patients the full picture. Here is what you should know:

Ketamine is not FDA-approved for ME/CFS. Its only FDA-approved indication is as an anesthetic. Use for fatigue, pain, and mood conditions is off-label.
Insurance typically does not cover it. IV ketamine infusions are an out-of-pocket expense for most patients. We have a detailed breakdown on our cost and pricing page.
The ME/CFS-specific evidence is preliminary. The mechanistic rationale is strong, and the adjacent evidence is encouraging, but we do not yet have the randomized controlled trials that would put this on firm clinical ground.
Response varies. Not every patient will respond, and we cannot predict in advance who will benefit most. Some patients notice improvement within the first few infusions. Others complete a full series without significant change.
It is not a cure. Ketamine may reduce symptoms and create space for other therapeutic work, but ME/CFS is a complex condition that will likely require ongoing management.

We share all of this during our consultation process. We would rather have an honest conversation upfront than have someone feel misled later.

Who Might Consider This

Based on the current evidence, ketamine for ME/CFS may be worth exploring if you have a confirmed ME/CFS diagnosis, have tried standard management approaches without adequate relief, experience significant pain or brain fog alongside your fatigue, and are looking for something that might reduce symptoms enough to re-engage with daily life or other treatments.

It is probably not the right fit if you are looking for a guaranteed solution, have medical contraindications to ketamine (we screen for these carefully), or are not comfortable with off-label use of a medication where the ME/CFS-specific evidence is still developing.

We serve patients from Nashville, Franklin, and across Middle Tennessee. If you are coming from farther away, we are happy to discuss logistics and help you plan around the treatment schedule.